To include your compound in the COVID-19 Resource Center, submit it here.

Mitobridge's DMD candidate MA-0211 enters Phase I

Mitobridge Inc. (Cambridge, Mass.) said that partner Astellas Pharma Inc. (Tokyo:4503) began

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE